Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
|Deserunt mollit sunt Lorem laborum do id aliqua dolore||03 Nov 2020||Lorem|
|Translate Bio’s Phase I/II mRNA replacement therapy for CF may be thwarted by delivery challenges, experts say||28 Feb 2019||Manasi Vaidya|
|Eloxx’s ELX-02 preclinical cystic fibrosis package needs more correlative CFTR data to predict clinical activity, experts say||28 Feb 2019||Manasi Vaidya|
|PTC’s Translarna unlikely to receive similar FDA approval leniency as Sarepta’s Exondys 51 in DMD given different scenarios – experts||27 Sep 2017||Hamish McDougall|
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Insight on companies’ CRO and business development needs, strategies and relationships
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer